What is Wedbush's Forecast for BCRX FY2025 Earnings?

Key Points

• Wedbush has raised its FY2025 earnings estimate for BioCryst Pharmaceuticals to $0.14 per share, up from $0.13, and maintains an "Outperform" rating with an $18.00 price target.
• BioCryst Pharmaceuticals recently reported earnings of $0.15 per share for the last quarter, significantly exceeding analysts' expectations of $0.03, alongside a 49.5% year-over-year revenue increase to $163.35 million.
• Institutional investors own 85.88% of BioCryst Pharmaceuticals' stock, indicating strong support from larger investment firms.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Wedbush raised their FY2025 earnings estimates for BioCryst Pharmaceuticals in a research note issued on Monday, August 4th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.14 for the year, up from their prior forecast of $0.13. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2029 earnings at $1.04 EPS.

BCRX has been the subject of a number of other research reports. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Finally, Bank of America increased their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $8.60 on Thursday. The firm has a market cap of $1.80 billion, a PE ratio of -47.78, a P/E/G ratio of 1.27 and a beta of 1.10. The firm has a 50 day simple moving average of $9.42 and a 200-day simple moving average of $8.74. BioCryst Pharmaceuticals has a 1-year low of $6.01 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. The business's revenue was up 49.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.06) EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BCRX. Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $32,000. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $33,000. GAMMA Investing LLC lifted its stake in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $62,000. Finally, Family Legacy Financial Solutions LLC acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter worth $72,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.